首页 > 最新文献

Circulation Reports最新文献

英文 中文
Content 内容
Pub Date : 2023-03-10 DOI: 10.1253/circrep.cr-5-content3
{"title":"Content","authors":"","doi":"10.1253/circrep.cr-5-content3","DOIUrl":"https://doi.org/10.1253/circrep.cr-5-content3","url":null,"abstract":"","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"263 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136096795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Utility of a Transcatheter Bubble Test for Platypnea-Orthodeoxia Syndrome in Adult Congenital Heart Disease With Chronic Obstructive Pulmonary Disease. 经导管气泡试验对成人先天性心脏病伴慢性阻塞性肺疾病的肺动脉-正氧综合征的诊断价值
Pub Date : 2023-03-10 DOI: 10.1253/circrep.CR-22-0119
Chiaki Yoshida, Hiroyuki Yamamoto, Akiko Masumoto, Hiroya Kawai, Tomofumi Takaya
Received November 21, 2022; revised manuscript received December 19, 2022; accepted January 17, 2023; J-STAGE Advance Publication released online February 11, 2023 Time for primary review: 23 days Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan Mailing address: Hiroyuki Yamamoto, MD, PhD, Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, 3-264 Kamiya-cho, Himeji 670-8560, Japan. email: y0493589 m@hotmail.co.jp All rights are reserved to the Japanese Circulation Society. For permissions, please email: cr@j-circ.or.jp ISSN-2434-0790 Diagnostic Utility of a Transcatheter Bubble Test for Platypnea-Orthodeoxia Syndrome in Adult Congenital Heart Disease With Chronic Obstructive Pulmonary Disease
{"title":"Diagnostic Utility of a Transcatheter Bubble Test for Platypnea-Orthodeoxia Syndrome in Adult Congenital Heart Disease With Chronic Obstructive Pulmonary Disease.","authors":"Chiaki Yoshida, Hiroyuki Yamamoto, Akiko Masumoto, Hiroya Kawai, Tomofumi Takaya","doi":"10.1253/circrep.CR-22-0119","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0119","url":null,"abstract":"Received November 21, 2022; revised manuscript received December 19, 2022; accepted January 17, 2023; J-STAGE Advance Publication released online February 11, 2023 Time for primary review: 23 days Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan Mailing address: Hiroyuki Yamamoto, MD, PhD, Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, 3-264 Kamiya-cho, Himeji 670-8560, Japan. email: y0493589 m@hotmail.co.jp All rights are reserved to the Japanese Circulation Society. For permissions, please email: cr@j-circ.or.jp ISSN-2434-0790 Diagnostic Utility of a Transcatheter Bubble Test for Platypnea-Orthodeoxia Syndrome in Adult Congenital Heart Disease With Chronic Obstructive Pulmonary Disease","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"97-98"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/03/circrep-5-97.PMC9992503.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9444929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interim Report of a Japanese Phase II Trial for Cardiac Stereotactic Body Radiotherapy in Refractory Ventricular Tachycardia - Focus on Target Determination. 日本一项心脏立体定向体放疗治疗难治性室性心动过速的II期试验的中期报告-重点是目标确定。
Pub Date : 2023-03-10 DOI: 10.1253/circrep.CR-23-0003
Mari Amino, Shigeto Kabuki, Etsuo Kunieda, Jun Hashimoto, Akitomo Sugawara, Tetsuri Sakai, Susumu Sakama, Kengo Ayabe, Yohei Ohno, Atsuhiko Yagishita, Yoshinori Kobayashi, Yuji Ikari, Koichiro Yoshioka

Background: Cardiac radiotherapy using stereotactic body radiation therapy (SBRT) has attracted attention as a minimally invasive treatment for refractory ventricular tachycardia. However, a standardized protocol and software program for determining the irradiation target have not been established. Here, we report the first preclinical stereotactic radioregulation antiarrhythmic therapy trial in Japan, focused on the target-setting process. Methods and Results: From 2019 onwards, 3 patients (age range 60-91 years) presenting with ischemic or non-ischemic cardiomyopathy were enrolled. Two patients were extremely serious and urgent, and were followed up for 6 and 30 months. To determine the irradiation targets, we aggregated electrophysiological, structural, and functional data and reflected them in an American Heart Association 17-segment model, as per the current recommendations. However, in all 3 patients, invasive electrophysiological study, phase-contrast computed tomography, and magnetic resonance imaging could not be performed; therefore, electrophysiological and structural information was limited. As alternatives, high-resolution ambulatory electrocardiography and nuclear medicine studies were useful in assessing arrhythmic substrates; however, concerns regarding test weighting and multiple scoring remain. Risks to surrounding organs were fully taken into account. Conclusions: In patients requiring cardiac SBRT, the information needed for target planning is sometimes limited to minimally invasive tests. Although there are issues to be resolved, this is a promising option for the life-saving treatment of patients in critical situations.

背景:立体定向体放射治疗(SBRT)作为一种微创治疗难治性室性心动过速的心脏放疗方法受到了广泛关注。然而,确定辐照目标的标准化方案和软件程序尚未建立。在这里,我们报告了日本的第一个临床前立体定向放射调节抗心律失常治疗试验,重点关注目标设定过程。方法和结果:从2019年起,纳入3例缺血性或非缺血性心肌病患者(年龄60-91岁)。其中2例为特重急症,随访6个月和30个月。为了确定照射目标,我们汇总了电生理、结构和功能数据,并按照目前的建议将其反映在美国心脏协会的17段模型中。然而,在所有3例患者中,均无法进行有创电生理研究、相对比计算机断层扫描和磁共振成像;因此,电生理和结构信息是有限的。作为替代方案,高分辨率动态心电图和核医学研究可用于评估心律失常底物;然而,关于考试权重和多重评分的担忧仍然存在。充分考虑了对周围器官的风险。结论:在需要心脏SBRT的患者中,目标规划所需的信息有时仅限于微创检查。虽然还有一些问题需要解决,但这是一个很有希望的选择,可以挽救危重患者的生命。
{"title":"Interim Report of a Japanese Phase II Trial for Cardiac Stereotactic Body Radiotherapy in Refractory Ventricular Tachycardia - Focus on Target Determination.","authors":"Mari Amino,&nbsp;Shigeto Kabuki,&nbsp;Etsuo Kunieda,&nbsp;Jun Hashimoto,&nbsp;Akitomo Sugawara,&nbsp;Tetsuri Sakai,&nbsp;Susumu Sakama,&nbsp;Kengo Ayabe,&nbsp;Yohei Ohno,&nbsp;Atsuhiko Yagishita,&nbsp;Yoshinori Kobayashi,&nbsp;Yuji Ikari,&nbsp;Koichiro Yoshioka","doi":"10.1253/circrep.CR-23-0003","DOIUrl":"https://doi.org/10.1253/circrep.CR-23-0003","url":null,"abstract":"<p><p><b><i>Background:</i></b> Cardiac radiotherapy using stereotactic body radiation therapy (SBRT) has attracted attention as a minimally invasive treatment for refractory ventricular tachycardia. However, a standardized protocol and software program for determining the irradiation target have not been established. Here, we report the first preclinical stereotactic radioregulation antiarrhythmic therapy trial in Japan, focused on the target-setting process. <b><i>Methods and Results:</i></b> From 2019 onwards, 3 patients (age range 60-91 years) presenting with ischemic or non-ischemic cardiomyopathy were enrolled. Two patients were extremely serious and urgent, and were followed up for 6 and 30 months. To determine the irradiation targets, we aggregated electrophysiological, structural, and functional data and reflected them in an American Heart Association 17-segment model, as per the current recommendations. However, in all 3 patients, invasive electrophysiological study, phase-contrast computed tomography, and magnetic resonance imaging could not be performed; therefore, electrophysiological and structural information was limited. As alternatives, high-resolution ambulatory electrocardiography and nuclear medicine studies were useful in assessing arrhythmic substrates; however, concerns regarding test weighting and multiple scoring remain. Risks to surrounding organs were fully taken into account. <b><i>Conclusions:</i></b> In patients requiring cardiac SBRT, the information needed for target planning is sometimes limited to minimally invasive tests. Although there are issues to be resolved, this is a promising option for the life-saving treatment of patients in critical situations.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"69-79"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/6e/circrep-5-69.PMC9992511.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Content 内容
Pub Date : 2023-02-10 DOI: 10.1253/circrep.cr-5-content2
{"title":"Content","authors":"","doi":"10.1253/circrep.cr-5-content2","DOIUrl":"https://doi.org/10.1253/circrep.cr-5-content2","url":null,"abstract":"","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136052064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Orthostatic Intolerance and Chronotropic Incompetence in Patients With Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. 肌痛性脑脊髓炎或慢性疲劳综合征患者的站立不耐受和变时功能不全。
Pub Date : 2023-02-10 DOI: 10.1253/circrep.CR-22-0114
Kunihisa Miwa

Background: Orthostatic intolerance markedly affects the day-to-day activities of patients with myalgic encephalomyelitis (ME) or chronic fatigue syndrome. Chronotropic incompetence (CI), defined as an impaired chronotropic response or reduced increases in heart rate during exercise and resulting in lower exercise capacity, may also be observed during orthostasis in patients with ME. Methods and Results: In this study, the recordings of 101 adult patients with ME (36 men, 65 women; mean [±SD] age 37±12 years) who underwent conventional active 10-min standing tests at least 3 times to determine the presence of CI were analyzed. Recordings were selected for 13 patients who experienced tests both with and without exhibiting postural orthostatic tachycardia syndrome (POTS; an increase in heart rate of ≥30 beats/min or an actual heart rate of ≥120 beats/min) while also both successfully completing and failing to complete 10-min standing on different occasions. Subjects in whom failure without POTS was observed in any test(s) while success was associated with POTS on other occasions were considered positive for CI during orthostasis. Of the 13 patients, 12 (92%) were CI positive, 5 (38%) of whom exclusively failed the tests without experiencing POTS. Conclusions: Some patients with ME were CI positive during standing tests, suggesting impaired sympathetic activation. The presence of POTS appears to be essential for maintaining orthostasis in these patients.

背景:站立不耐受明显影响肌痛性脑脊髓炎(ME)或慢性疲劳综合征患者的日常活动。变时性无能(CI),定义为运动时变时反应受损或心率增加减少,导致运动能力降低,也可在ME患者站立时观察到。方法与结果:本研究收集了101例成年ME患者(男性36例,女性65例;平均[±SD]年龄37±12岁),接受至少3次常规10分钟站立试验以确定CI的存在。选取13例有或无体位性站立性心动过速综合征(POTS;心率增加≥30次/分或实际心率≥120次/分),同时在不同场合站立10分钟成功或失败。在任何测试中观察到不使用POTS失败而在其他情况下使用POTS成功的受试者被认为在直立期间CI阳性。在13例患者中,12例(92%)CI阳性,其中5例(38%)完全未通过检测而未经历POTS。结论:一些ME患者在站立试验时CI呈阳性,提示交感神经激活受损。POTS的存在似乎对维持这些患者的直立性是必不可少的。
{"title":"Orthostatic Intolerance and Chronotropic Incompetence in Patients With Myalgic Encephalomyelitis or Chronic Fatigue Syndrome.","authors":"Kunihisa Miwa","doi":"10.1253/circrep.CR-22-0114","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0114","url":null,"abstract":"<p><p><b><i>Background:</i></b> Orthostatic intolerance markedly affects the day-to-day activities of patients with myalgic encephalomyelitis (ME) or chronic fatigue syndrome. Chronotropic incompetence (CI), defined as an impaired chronotropic response or reduced increases in heart rate during exercise and resulting in lower exercise capacity, may also be observed during orthostasis in patients with ME. <b><i>Methods and Results:</i></b> In this study, the recordings of 101 adult patients with ME (36 men, 65 women; mean [±SD] age 37±12 years) who underwent conventional active 10-min standing tests at least 3 times to determine the presence of CI were analyzed. Recordings were selected for 13 patients who experienced tests both with and without exhibiting postural orthostatic tachycardia syndrome (POTS; an increase in heart rate of ≥30 beats/min or an actual heart rate of ≥120 beats/min) while also both successfully completing and failing to complete 10-min standing on different occasions. Subjects in whom failure without POTS was observed in any test(s) while success was associated with POTS on other occasions were considered positive for CI during orthostasis. Of the 13 patients, 12 (92%) were CI positive, 5 (38%) of whom exclusively failed the tests without experiencing POTS. <b><i>Conclusions:</i></b> Some patients with ME were CI positive during standing tests, suggesting impaired sympathetic activation. The presence of POTS appears to be essential for maintaining orthostasis in these patients.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 2","pages":"55-61"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/e8/circrep-5-55.PMC9908528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10772735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Omentin Modulates Chronic Cardiac Remodeling After Myocardial Infarction. 大网膜蛋白调节心肌梗死后慢性心脏重构。
Pub Date : 2023-02-10 DOI: 10.1253/circrep.CR-22-0079
Masanori Ito, Rei Shibata, Koji Ohashi, Naoya Otaka, Shukuro Yamaguchi, Hayato Ogawa, Takashi Enomoto, Tomohiro Masutomi, Toyoaki Murohara, Noriyuki Ouchi

Background: Omentin, a circulating adipokine, is downregulated in complications of obesity, including heart disease. Here, we investigated whether omentin modulates adverse cardiac remodeling in mice after myocardial infarction (MI). Methods and Results: Transgenic mice expressing the human omentin gene in fat tissue (OMT-Tg) and wild-type (WT) mice were subjected to permanent ligation of the left anterior descending coronary artery (LAD) to induce MI. OMT-Tg mice had a higher survival rate after permanent LAD ligation than WT mice. Moreover, OMT-Tg mice had lower heart weight/body weight (HW/BW) and lung weight/body weight (LW/BW) ratios at 4 weeks after coronary artery ligation compared with WT mice. OMT-Tg mice also showed decreased left ventricular diastolic diameter (LVDd) and increased fractional shortening (%FS) following MI. Moreover, an increase in capillary density in the infarct border zone and a decrease in myocardial apoptosis, myocyte hypertrophy, and interstitial fibrosis in the remote zone following MI, were more prevalent in OMT-Tg than WT mice. Finally, intravenous administration of adenoviral vectors expressing human omentin to WT mice after MI resulted in decreases in HW/BW, LW/BW, and LVDd, and an increase in %FS. Conclusions: Our findings document that human omentin prevents pathological cardiac remodeling after chronic ischemia, suggesting that omentin represents a potential therapeutic molecule for the treatment of ischemic heart disease.

背景:Omentin是一种循环脂肪因子,在包括心脏病在内的肥胖并发症中下调。在这里,我们研究大网膜蛋白是否调节心肌梗死(MI)后小鼠的不良心脏重构。方法与结果:将脂肪组织中表达人网膜基因的转基因小鼠(OMT-Tg)和野生型小鼠(WT)永久性结扎左冠状动脉前降支(LAD)诱导心肌梗死,永久性结扎后OMT-Tg小鼠的存活率高于野生型小鼠。此外,在冠状动脉结扎后4周,OMT-Tg小鼠的心脏重量/体重(HW/BW)和肺重量/体重(LW/BW)比WT小鼠低。心肌梗死后,OMT-Tg小鼠左室舒张直径(LVDd)降低,分数缩短(%FS)增加。此外,心肌梗死后,梗死边缘区毛细血管密度增加,心肌凋亡、心肌细胞肥大和远端区间质纤维化减少,在OMT-Tg小鼠中比WT小鼠更为普遍。最后,在心肌梗死后,WT小鼠静脉注射表达人网膜蛋白的腺病毒载体,导致HW/BW、LW/BW和LVDd降低,FS %增加。结论:我们的研究结果表明,人大网膜可预防慢性缺血后的病理性心脏重塑,提示大网膜可能是治疗缺血性心脏病的潜在治疗分子。
{"title":"Omentin Modulates Chronic Cardiac Remodeling After Myocardial Infarction.","authors":"Masanori Ito,&nbsp;Rei Shibata,&nbsp;Koji Ohashi,&nbsp;Naoya Otaka,&nbsp;Shukuro Yamaguchi,&nbsp;Hayato Ogawa,&nbsp;Takashi Enomoto,&nbsp;Tomohiro Masutomi,&nbsp;Toyoaki Murohara,&nbsp;Noriyuki Ouchi","doi":"10.1253/circrep.CR-22-0079","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0079","url":null,"abstract":"<p><p><b><i>Background:</i></b> Omentin, a circulating adipokine, is downregulated in complications of obesity, including heart disease. Here, we investigated whether omentin modulates adverse cardiac remodeling in mice after myocardial infarction (MI). <b><i>Methods and Results:</i></b> Transgenic mice expressing the human omentin gene in fat tissue (OMT-Tg) and wild-type (WT) mice were subjected to permanent ligation of the left anterior descending coronary artery (LAD) to induce MI. OMT-Tg mice had a higher survival rate after permanent LAD ligation than WT mice. Moreover, OMT-Tg mice had lower heart weight/body weight (HW/BW) and lung weight/body weight (LW/BW) ratios at 4 weeks after coronary artery ligation compared with WT mice. OMT-Tg mice also showed decreased left ventricular diastolic diameter (LVDd) and increased fractional shortening (%FS) following MI. Moreover, an increase in capillary density in the infarct border zone and a decrease in myocardial apoptosis, myocyte hypertrophy, and interstitial fibrosis in the remote zone following MI, were more prevalent in OMT-Tg than WT mice. Finally, intravenous administration of adenoviral vectors expressing human omentin to WT mice after MI resulted in decreases in HW/BW, LW/BW, and LVDd, and an increase in %FS. <b><i>Conclusions:</i></b> Our findings document that human omentin prevents pathological cardiac remodeling after chronic ischemia, suggesting that omentin represents a potential therapeutic molecule for the treatment of ischemic heart disease.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 2","pages":"46-54"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/62/circrep-5-46.PMC9908527.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10756702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Intravenous Diuretic Use to Treat Congestion in Patients With Heart Failure - An Observational Study Using a Research Database. 静脉利尿剂用于治疗心力衰竭患者的充血-一项使用研究数据库的观察性研究。
Pub Date : 2023-02-10 DOI: 10.1253/circrep.CR-22-0091
Yasuyuki Shiraishi, Yuka Kurita, Miyuki Matsukawa, Hiromasa Mori

Background: Intravenous (IV) diuretics are key in the treatment of acute heart failure, but the time of administration can affect outcomes. Using a medical database, we assessed the real-world usage and clinical impact of IV diuretics after admission. Methods and Results: This observational study included hospitalized patients with heart failure who received IV diuretics. Relationships between IV diuretic use and clinical outcomes (duration of hospitalization, in-hospital mortality, readmission) were evaluated using analysis of variance or logistic regression. Overall, 9,653 patients (51.1% male) were assessed (mean age 80.9 years). Most (89.1%) patients had IV loop diuretic treatment initiated on Day 1 of hospitalization and 68.0% achieved the maximum dose on that day. The median duration of hospitalization was 17.0 days. In-hospital mortality was 9.2%; 13.7% of patients were readmitted within 3 months after discharge. There were prognostic relationships between IV diuretic usage and both duration of hospitalization and in-hospital mortality. On multivariable analysis, the time of maximum dose had the biggest impact on outcomes. Duration of hospitalization was prolonged and in-hospital mortality rates increased when the time of maximum dose was delayed. There was little correlation between IV diuretic use and readmission following discharge. Conclusions: Short-term outcomes (duration of hospitalization, in-hospital mortality) correlated with the time of maximum IV diuretic dose; thus, early initiation and subsequent modification of appropriate congestion treatment is critical for prognostic improvement.

背景:静脉(IV)利尿剂是治疗急性心力衰竭的关键,但给药时间会影响结果。利用医学数据库,我们评估了入院后静脉利尿剂的实际使用情况和临床影响。方法和结果:这项观察性研究纳入了接受静脉利尿剂治疗的住院心力衰竭患者。静脉利尿剂使用与临床结果(住院时间、住院死亡率、再入院)之间的关系通过方差分析或logistic回归进行评估。总体而言,9653例患者(51.1%为男性)被评估(平均年龄80.9岁)。大多数(89.1%)患者在住院第1天开始静脉循环利尿剂治疗,68.0%的患者在当天达到最大剂量。中位住院时间为17.0天。住院死亡率为9.2%;13.7%的患者出院后3个月内再次入院。静脉利尿剂的使用与住院时间和住院死亡率之间存在预后关系。在多变量分析中,最大剂量时间对结果的影响最大。最大剂量时间延迟,住院时间延长,住院死亡率增加。静脉利尿剂的使用与出院后再入院的关系不大。结论:短期预后(住院时间、住院死亡率)与最大静脉利尿剂剂量时间相关;因此,早期开始和随后修改适当的充血治疗是预后改善的关键。
{"title":"Real-World Intravenous Diuretic Use to Treat Congestion in Patients With Heart Failure - An Observational Study Using a Research Database.","authors":"Yasuyuki Shiraishi,&nbsp;Yuka Kurita,&nbsp;Miyuki Matsukawa,&nbsp;Hiromasa Mori","doi":"10.1253/circrep.CR-22-0091","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0091","url":null,"abstract":"<p><p><b><i>Background:</i></b> Intravenous (IV) diuretics are key in the treatment of acute heart failure, but the time of administration can affect outcomes. Using a medical database, we assessed the real-world usage and clinical impact of IV diuretics after admission. <b><i>Methods and Results:</i></b> This observational study included hospitalized patients with heart failure who received IV diuretics. Relationships between IV diuretic use and clinical outcomes (duration of hospitalization, in-hospital mortality, readmission) were evaluated using analysis of variance or logistic regression. Overall, 9,653 patients (51.1% male) were assessed (mean age 80.9 years). Most (89.1%) patients had IV loop diuretic treatment initiated on Day 1 of hospitalization and 68.0% achieved the maximum dose on that day. The median duration of hospitalization was 17.0 days. In-hospital mortality was 9.2%; 13.7% of patients were readmitted within 3 months after discharge. There were prognostic relationships between IV diuretic usage and both duration of hospitalization and in-hospital mortality. On multivariable analysis, the time of maximum dose had the biggest impact on outcomes. Duration of hospitalization was prolonged and in-hospital mortality rates increased when the time of maximum dose was delayed. There was little correlation between IV diuretic use and readmission following discharge. <b><i>Conclusions:</i></b> Short-term outcomes (duration of hospitalization, in-hospital mortality) correlated with the time of maximum IV diuretic dose; thus, early initiation and subsequent modification of appropriate congestion treatment is critical for prognostic improvement.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 2","pages":"27-37"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/cf/circrep-5-27.PMC9908529.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10763893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Kagoshima-DVT Score Is a Useful Predictive Model for Cancer-Associated Thrombosis in Patients With Gastrointestinal Cancer. 鹿儿岛- dvt评分是胃肠道肿瘤患者癌症相关血栓形成的有效预测模型。
Pub Date : 2023-02-10 DOI: 10.1253/circrep.CR-22-0112
Keisuke Shibata, Akihiro Tokushige, Yuki Hamamoto, Koji Higuchi, Masakazu Imamura, Yoshiyuki Ikeda, Mitsuru Ohishi

Background: Cancer-associated thrombosis (CAT) is a common complication of cancer and has received increasing attention; the Khorana Risk Score (KRS) is a recommended but insufficient risk assessment model for CAT. We propose a novel Kagoshima-DVT score (KDS) to predict preoperative deep vein thrombosis (DVT). This scoring method scores D-dimer ≥1.5 μg/mL, age ≥60 years, female sex, ongoing glucocorticoids, cancer with high risk of DVT, and prolonged immobility. The purpose of this study was to compare the performance of the KDS and KRS in predicting CAT in patients with gastrointestinal cancer. Methods and Results: In all, 250 patients without a history of thrombosis who received their first chemotherapy for gastrointestinal cancer were divided into low- (48.0%), intermediate- (38.8%), and high-risk (13.2%) groups for CAT development by the KDS. The patients' median age was 67 years and 63.2% were men. In all, 61 (27.1%) patients developed CAT (17.6%, 35.3%, and 36.4% of patients in the low-, intermediate, and high-risk groups, respectively; log-rank P=0.006). The area under the time-dependent receiver operating characteristic curve for CAT occurrence within 1 year was larger for the KDS than KRS (0.653 vs. 0.494). Conclusions: A high KDS at the start of first chemotherapy is a risk indicator for CAT development during chemotherapy. Moreover, the KDS is more useful than the KRS in predicting CAT risk.

背景:癌症相关血栓形成(cancer -associated thrombosis, CAT)是癌症的常见并发症,已受到越来越多的关注;Khorana风险评分(KRS)是一种推荐的但不充分的CAT风险评估模型。我们提出一种新的Kagoshima-DVT评分(KDS)来预测术前深静脉血栓形成(DVT)。该评分方法对d -二聚体≥1.5 μg/mL、年龄≥60岁、女性、持续使用糖皮质激素、深静脉血栓高危癌、长期不活动进行评分。本研究的目的是比较KDS和KRS在预测胃肠道肿瘤患者CAT方面的表现。方法和结果:总共250例无血栓形成史的首次接受胃肠道肿瘤化疗的患者被KDS分为低(48.0%)、中(38.8%)和高风险(13.2%)组。患者中位年龄为67岁,男性占63.2%。总共有61例(27.1%)患者发生了CAT(分别为低、中、高风险组患者的17.6%、35.3%和36.4%);log-rank P = 0.006)。1年内发生CAT的时间依赖性受试者工作特征曲线下面积KDS大于KRS(0.653比0.494)。结论:首次化疗开始时的高KDS是化疗期间发生CAT的危险指标。此外,KDS比KRS在预测CAT风险方面更有用。
{"title":"The Kagoshima-DVT Score Is a Useful Predictive Model for Cancer-Associated Thrombosis in Patients With Gastrointestinal Cancer.","authors":"Keisuke Shibata,&nbsp;Akihiro Tokushige,&nbsp;Yuki Hamamoto,&nbsp;Koji Higuchi,&nbsp;Masakazu Imamura,&nbsp;Yoshiyuki Ikeda,&nbsp;Mitsuru Ohishi","doi":"10.1253/circrep.CR-22-0112","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0112","url":null,"abstract":"<p><p><b><i>Background:</i></b> Cancer-associated thrombosis (CAT) is a common complication of cancer and has received increasing attention; the Khorana Risk Score (KRS) is a recommended but insufficient risk assessment model for CAT. We propose a novel Kagoshima-DVT score (KDS) to predict preoperative deep vein thrombosis (DVT). This scoring method scores D-dimer ≥1.5 μg/mL, age ≥60 years, female sex, ongoing glucocorticoids, cancer with high risk of DVT, and prolonged immobility. The purpose of this study was to compare the performance of the KDS and KRS in predicting CAT in patients with gastrointestinal cancer. <b><i>Methods and Results:</i></b> In all, 250 patients without a history of thrombosis who received their first chemotherapy for gastrointestinal cancer were divided into low- (48.0%), intermediate- (38.8%), and high-risk (13.2%) groups for CAT development by the KDS. The patients' median age was 67 years and 63.2% were men. In all, 61 (27.1%) patients developed CAT (17.6%, 35.3%, and 36.4% of patients in the low-, intermediate, and high-risk groups, respectively; log-rank P=0.006). The area under the time-dependent receiver operating characteristic curve for CAT occurrence within 1 year was larger for the KDS than KRS (0.653 vs. 0.494). <b><i>Conclusions:</i></b> A high KDS at the start of first chemotherapy is a risk indicator for CAT development during chemotherapy. Moreover, the KDS is more useful than the KRS in predicting CAT risk.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 2","pages":"19-26"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/e0/circrep-5-19.PMC9908526.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10772734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Delivery of the Navitor Transcatheter Heart Valve Using an Expandable Sheath via a Heavily Calcified Iliac Artery Access Route. 经严重钙化的髂动脉通路,使用可扩张护套,成功递送Navitor经导管心脏瓣膜。
Pub Date : 2023-02-10 DOI: 10.1253/circrep.CR-22-0122
Hiroto Nishio, Masanori Yamamoto, Masahiro Uehara, Ai Kagase, Takahiro Tokuda
{"title":"Successful Delivery of the Navitor Transcatheter Heart Valve Using an Expandable Sheath via a Heavily Calcified Iliac Artery Access Route.","authors":"Hiroto Nishio,&nbsp;Masanori Yamamoto,&nbsp;Masahiro Uehara,&nbsp;Ai Kagase,&nbsp;Takahiro Tokuda","doi":"10.1253/circrep.CR-22-0122","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0122","url":null,"abstract":"","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 2","pages":"66-67"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f5/ad/circrep-5-66.PMC9908521.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10767439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study Protocol of Cardiac Rehabilitation for Acute Myocardial Infarction From the JROAD/JROAD-DPC Database - JROAD-CR. 来自JROAD/JROAD- dpc数据库- JROAD- cr的急性心肌梗死心脏康复研究方案。
Pub Date : 2023-02-10 DOI: 10.1253/circrep.CR-22-0121
Yasunori Suematsu, Shin-Ichiro Miura, Akira Minei, Yoko Sumita, Koshiro Kanaoka, Michikazu Nakai, Hisatomi Arima, Koshi Nakamura, Tomoyuki Takura, Kazunori Shimada, Hirokazu Shiraishi, Nagaharu Fukuma, Yusuke Ohya, Shigeru Makita

Background: Although cardiac rehabilitation (CR) has been reported to be effective for improving the prognosis of acute myocardial infarction (AMI), more patients must participate in CR during admission and as outpatients. Factors contributing to, and countermeasures against, the low CR participation rate need to be identified. Here we describe the protocol for a study designed to evaluate the effectiveness and problems of CR for AMI from the Japanese Registry of All Cardiac and Vascular Diseases (JROAD) and the JROAD-Japanese Diagnosis Procedure Combination system (JROAD-DPC) database. Methods and Results: This is a multicenter retrospective cohort study that will use the JROAD/JROAD-DPC database to evaluate the effectiveness of CR for AMI (JROAD-CR). Five thousand patients with AMI who were admitted to hospitals registered in the JROAD database in 2014 will be investigated with regard to their baseline characteristics, AMI severity and treatment, examination results, history of CR, and prognosis up to 5 years. We will also investigate the presence, quantity, and quality of CR, and evaluate the effectiveness of CR with respect to cost, exercise tolerance, and prognosis during admission and follow-up. Conclusions: The JROAD-CR study will seek to reveal the effectiveness of CR for AMI in the era of early reperfusion therapy and shortened hospitalization.

背景:虽然心脏康复(CR)已被报道对改善急性心肌梗死(AMI)的预后有效,但更多的患者必须在入院时和作为门诊患者参与CR。企业社会责任参与率低的原因和对策需要明确。在这里,我们描述了一项研究的方案,该研究旨在评估日本所有心脏和血管疾病登记处(JROAD)和JROAD-日本诊断程序组合系统(JROAD- dpc)数据库中CR对AMI的有效性和问题。方法和结果:这是一项多中心回顾性队列研究,将使用JROAD/JROAD- dpc数据库来评估CR治疗AMI的有效性(JROAD-CR)。本研究将调查2014年在JROAD数据库中登记的医院收治的5000名AMI患者的基线特征、AMI严重程度和治疗、检查结果、CR史以及长达5年的预后。我们还将调查CR的存在、数量和质量,并在入院和随访期间评估CR在成本、运动耐量和预后方面的有效性。结论:JROAD-CR研究旨在揭示CR在早期再灌注治疗和缩短住院时间时代对AMI的有效性。
{"title":"Study Protocol of Cardiac Rehabilitation for Acute Myocardial Infarction From the JROAD/JROAD-DPC Database - JROAD-CR.","authors":"Yasunori Suematsu,&nbsp;Shin-Ichiro Miura,&nbsp;Akira Minei,&nbsp;Yoko Sumita,&nbsp;Koshiro Kanaoka,&nbsp;Michikazu Nakai,&nbsp;Hisatomi Arima,&nbsp;Koshi Nakamura,&nbsp;Tomoyuki Takura,&nbsp;Kazunori Shimada,&nbsp;Hirokazu Shiraishi,&nbsp;Nagaharu Fukuma,&nbsp;Yusuke Ohya,&nbsp;Shigeru Makita","doi":"10.1253/circrep.CR-22-0121","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0121","url":null,"abstract":"<p><p><b><i>Background:</i></b> Although cardiac rehabilitation (CR) has been reported to be effective for improving the prognosis of acute myocardial infarction (AMI), more patients must participate in CR during admission and as outpatients. Factors contributing to, and countermeasures against, the low CR participation rate need to be identified. Here we describe the protocol for a study designed to evaluate the effectiveness and problems of CR for AMI from the Japanese Registry of All Cardiac and Vascular Diseases (JROAD) and the JROAD-Japanese Diagnosis Procedure Combination system (JROAD-DPC) database. <b><i>Methods and Results:</i></b> This is a multicenter retrospective cohort study that will use the JROAD/JROAD-DPC database to evaluate the effectiveness of CR for AMI (JROAD-CR). Five thousand patients with AMI who were admitted to hospitals registered in the JROAD database in 2014 will be investigated with regard to their baseline characteristics, AMI severity and treatment, examination results, history of CR, and prognosis up to 5 years. We will also investigate the presence, quantity, and quality of CR, and evaluate the effectiveness of CR with respect to cost, exercise tolerance, and prognosis during admission and follow-up. <b><i>Conclusions:</i></b> The JROAD-CR study will seek to reveal the effectiveness of CR for AMI in the era of early reperfusion therapy and shortened hospitalization.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 2","pages":"62-65"},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/6f/circrep-5-62.PMC9908525.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10756701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Circulation Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1